Kanghong Pharmaceutical (002773.SZ) obtained ibutinib capsule drug registration certificate

Zhitongcaijing · 2d ago

Zhitong Finance App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. The company recently received the “Drug Registration Certificate” for ibutinib capsules issued by the State Drug Administration. Ibutinib is a small-molecule BTK (Bruton tyrosine kinase) inhibitor that forms covalent bonds with cysteine residues at BTK active sites, thereby inhibiting BTK's enzymatic activity. BTK is a signaling molecule for the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK activates pathways necessary for B-cell migration, chemotaxis, and adhesion through B-cell surface receptor signaling.